Time-Lapse Imaging to Analyze Cell Fate in Response to Antimitotics.

Patrícia M A Silva, João P N Silva, Bárbara Pinto, Hassan Bousbaa

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Patrícia M A SilvaUNIPRO - Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal. patricia.silva@cespu.pt.

João P N SilvaUNIPRO - Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal.

Bárbara PintoUNIPRO - Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal.

Hassan BousbaaUNIPRO - Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal. hassan.bousbaa@iucs.cespu.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Time-lapse imaging is a powerful technique widely used in Cellular and Molecular Biology to capture and analyze the dynamic processes of living cells over specific time periods. Particularly, in the study of cell division, under normal conditions or after drug treatments, this methodology can provide essential data that is impossible to obtain from conventional cell-fixed-based assays. In the context of evaluating cell fate after antimitotic drug treatment, time-lapse imaging provides valuable insights into the mechanisms of action of these compounds. Antimitotic drugs belong to a class of anticancer compounds that interfere with mitosis by targeting microtubules or specific kinases and molecular motors involved in the mitotic apparatus. This chapter aims to highlight the significant advantage of using time-lapse microscopy to assess the effects of antimitotic drugs on cell behavior and fates. We describe the full protocol for time-lapse imaging, using the human lung adenocarcinoma A549 cell line as a model, after exposure to the antimitotic BI2536, a potent inhibitor of polo-like kinase 1 (PLK1). This description includes software for imaging acquisition and data analysis.

Indexed as

Antimitotic AgentsMitosisProtein Serine-Threonine KinasesTime-Lapse ImagingA549 CellsCell Cycle ProteinsCell Line, TumorHumansImage Processing, Computer-AssistedPolo-Like Kinase 1Proto-Oncogene ProteinsPteridinesAntimitotic AgentsBI 2536Cell Cycle ProteinsPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsPteridinesAntimitotic agentsBI2536Cell dynamicsCell fateCell trackingPolo-like kinase 1Time-lapse imaging

Identifiers

PMID39614051

DOI10.1016/j.tranon.2016.10.003

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.